AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

Qpex’s pipeline revolves around xeruborbactam, an extended-spectrum beta-lactamase inhibitor that is in early-stage clinical testing in both intravenous and oral combinations for infections ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

It is, however, a beta-lactamase inhibitor of the Molecular class A enzymes, including Richmond-Sykes class III (Bush class 2b & 2b') penicillinases and cephalosporinases. It varies in its ability ...

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

His main research interest is understanding the molecular basis of beta-lactamase-mediated antibiotic resistance ... Currently, in his role as a postdoctoral fellow at Palzkill Lab, he investigates ...

Together, they’re being studied as a potential treatment option for serious bacterial infections caused by antibiotic-resistant gram-negative bacteria, including Extended Spectrum Beta-lactamase ...

Among children treated with an oral agent, the recurrence rate was 16/42 (38.1%) following penicillin or amoxicillin and 10/36 (27.8%) following a beta-lactamase resistant agent (adjusted odds ...